Pozzi L, Invernizzi R, Cervo L, Vallebuona F, Samanin R
Instituto di Ricerche Farmacologiche Mario Negri, Milan, Italy.
J Neurochem. 1994 Jul;63(1):195-200. doi: 10.1046/j.1471-4159.1994.63010195.x.
Experiments were performed to confirm that noradrenergic terminals regulate extracellular concentrations of dopamine (DA) in the frontal cortex of rats. The effects of 20 mg/kg 1-[2-[bis(4-fluorphenyl)methoxy]-ethyl]-4-(3- phenylpropyl)piperazine (GBR 12909), a selective inhibitor of DA uptake, and 2.5 mg/kg desipramine (DMI) on the extracellular concentrations of DA in the frontal cortex and striatum were studied in rats given 6-hydroxydopamine (6 micrograms/microliters) bilaterally into the locus coeruleus to destroy noradrenergic terminals. GBR 12909 increased dialysate DA similarly in the striatum of vehicle and 6-hydroxydopamine-treated rats, whereas in the frontal cortex it raised DA concentrations only in lesioned animals. DMI raised extracellular DA concentrations in the frontal cortex but not in the striatum of controls. The effect of DMI on cortical DA was abolished by the 6-hydroxydopamine lesion. GBR 12909, at a subcutaneous dose of 20 mg/kg, further increased cortical dialysate DA in rats given DMI intraperitoneally at 20 mg/kg or through the probe at 10(-5) mol/L. The data support the hypothesis of an important regulation of the extracellular concentrations of DA in the frontal cortex by noradrenergic terminals.
进行实验以证实去甲肾上腺素能终末调节大鼠额叶皮质中多巴胺(DA)的细胞外浓度。在双侧向蓝斑注射6 - 羟基多巴胺(6微克/微升)以破坏去甲肾上腺素能终末的大鼠中,研究了20毫克/千克的1 - [2 - [双(4 - 氟苯基)甲氧基] - 乙基] - 4 - (3 - 苯基丙基)哌嗪(GBR 12909,一种DA摄取的选择性抑制剂)和2.5毫克/千克地昔帕明(DMI)对额叶皮质和纹状体中DA细胞外浓度的影响。GBR 12909在给予赋形剂的大鼠和6 - 羟基多巴胺处理的大鼠的纹状体中同样增加了透析液中的DA,而在额叶皮质中,它仅在受损动物中提高了DA浓度。DMI提高了对照组额叶皮质中的细胞外DA浓度,但未提高纹状体中的浓度。6 - 羟基多巴胺损伤消除了DMI对皮质DA的作用。皮下剂量为20毫克/千克的GBR 12909进一步增加了腹腔注射20毫克/千克或通过探针给予10(-5)摩尔/升DMI的大鼠的皮质透析液DA。这些数据支持去甲肾上腺素能终末对额叶皮质中DA细胞外浓度进行重要调节的假说。